NASDAQ:MCRBSeres Therapeutics Stock Price, Forecast & News

Seres Therapeutics' stock was trading at $2.64 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, MCRB shares have increased by 81.8% and is now trading at $4.80. View which stocks have been most impacted by Coronavirus.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Seres Therapeutics in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Seres Therapeutics.

Seres Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Seres Therapeutics.

Seres Therapeutics Inc (NASDAQ:MCRB) released its quarterly earnings results on Thursday, May, 7th. The biotechnology company reported ($0.28) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.28). The biotechnology company earned $8.19 million during the quarter, compared to the consensus estimate of $8.01 million. View Seres Therapeutics' earnings history.

5 analysts have issued 12-month price targets for Seres Therapeutics' shares. Their forecasts range from $7.00 to $12.50. On average, they anticipate Seres Therapeutics' stock price to reach $9.63 in the next twelve months. This suggests a possible upside of 100.5% from the stock's current price. View analysts' price targets for Seres Therapeutics.

News stories about MCRB stock have trended very negative this week, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Seres Therapeutics earned a coverage optimism score of -3.3 on InfoTrie's scale. They also assigned media headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near term. View the latest news about Seres Therapeutics.

Seres Therapeutics saw a increase in short interest during the month of June. As of June 15th, there was short interest totaling 6,740,000 shares, an increase of 8.7% from the May 31st total of 6,200,000 shares. Based on an average daily trading volume, of 399,700 shares, the days-to-cover ratio is presently 16.9 days. Currently, 15.7% of the shares of the company are short sold. View Seres Therapeutics' Current Options Chain.

Some companies that are related to Seres Therapeutics include Odonate Therapeutics (ODT), Heron Therapeutics (HRTX), Theravance Biopharma (TBPH), Karyopharm Therapeutics (KPTI), Esperion Therapeutics (ESPR), Tricida (TCDA), ZEALAND PHARMA/S (ZEAL), I-Mab (ARQT), Arvinas (ARVN), Supernus Pharmaceuticals (SUPN), Legend Biotech (PLRX), Constellation Pharmaceuticals (CNST), Rocket Pharmaceuticals (RCKT), Athenex (ATNX) and Aimmune Therapeutics (AIMT). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Seres Therapeutics investors own include Opko Health (OPK), TherapeuticsMD (TXMD), Juno Therapeutics (JUNO), Walt Disney (DIS), NVIDIA (NVDA), Alibaba Group (BABA), Novavax (NVAX), BioCryst Pharmaceuticals (BCRX), Exelixis (EXEL) and Gilead Sciences (GILD).

(MCRB) raised $101 million in an initial public offering on Friday, June 26th 2015. The company issued 6,300,000 shares at $15.00-$17.00 per share. Goldman Sachs and BofA Merrill Lynch served as the underwriters for the IPO and Leerink Partners and Canaccord Genuity were co-managers.

Seres Therapeutics trades on the NASDAQ under the ticker symbol "MCRB."

Shares of MCRB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of MCRB stock can currently be purchased for approximately $4.80.

Seres Therapeutics has a market capitalization of $348.48 million and generates $34.51 million in revenue each year. The biotechnology company earns $-70,280,000.00 in net income (profit) each year or ($1.20) on an earnings per share basis. Seres Therapeutics employs 145 workers across the globe.

The official website for Seres Therapeutics is www.serestherapeutics.com.

Seres Therapeutics' mailing address is 200 SIDNEY STREET - 4TH FLOOR, CAMBRIDGE MA, 02139. The biotechnology company can be reached via phone at 617-945-9626 or via email at [email protected]